Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5634
Peer-review started: December 27, 2021
First decision: January 25, 2022
Revised: February 11, 2022
Accepted: April 9, 2022
Article in press: April 29, 2022
Published online: June 16, 2022
Processing time: 164 Days and 3.1 Hours
Intestinal fluorine-18 fluorodeoxyglucose (F-18 FDG) uptake is often observed on positron emission tomography/computed tomography (PET/CT). However, unexpectedly observed focal colorectal hypermetabolism might harbor a risk of malignancy; thus, distinguishing malignant from benign tumors is critical.
As with other cancers, early lesion detection is critical in colorectal cancer. As surgery may still be the treatment of choice for cure in selected patients with advanced colorectal cancer, the importance of early detection of lesions is even greater.
To assess the implications of focal colorectal F-18 FDG uptake by analyzing FDG PET parameters.
This study included 83 focal colorectal hypermetabolic regions from 80 patients. Each region was classified as malignant, premalignant, or benign according to the histopathological report. PET parameters such as maximum and peak standardized uptake values (SUVmax and SUVpeak), metabolic tumor volume (MTV), mean SUV of metabolic tumor volume (mSUVmtv), and total lesion glycolysis (TLG) of F-18 FDG PET/CT were measured and calculated for the regions, and compared among malignant, premalignant, malignant/premalignant, and benign hypermetabolic regions. Receiver operating characteristic (ROC) curves were plotted to determine the cut-off values for these parameters.
Of the 83 incidentally observed focal colorectal hypermetabolic regions on F-18 FDG PET-CT, 61.4% (51/83) were malignant/premalignant lesions confirmed by histopathological reports of the corresponding locations. SUVmax, SUVpeak, and mSUVmtv can be used to differentiate malignant and premalignant lesions from benign lesions. SUVmax, with an AUC of 0.770 and a cut-off of 7.6 (confidence interval: 0.668–0.872, sensitivity 0.686, specificity 0.688) was the superior FDG PET parameter in distinguishing malignant and premalignant from benign lesions.
Approximately two-thirds (61.4%) of the incidental focal hypermetabolic colorectal regions were malignant/premalignant. SUVmax was demonstrated as an independent diagnostic parameter for the lesions. Unexpected suspicious focal colorectal FDG uptake should not be avoided and further evaluation is required.
Controversies and debates regarding the parameters assessed in this study remain ongoing. Further studies with larger numbers of subjects are warranted.